Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „ranolazine“
Suchtreffer
Begriffe & Kennungen
Ranexa (previously Latixa) · 4.5 · CYP3A4 or P-gp inhibitors: Ranolazine is a substrate of cytochrome CYP3A4. Inhibitors of CYP3A4 increase plasm
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Effects of other medicinal products on ranolazine
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Effects of other medicinal products on ranolazine
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Effects of other medicinal products on ranolazine
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Effects of ranolazine on other medicinal products
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Effects of ranolazine on other medicinal products
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Ranolazine is a moderate to potent inhibitor of P-gp and a mild inhibitor of CYP3A4, and may increase plasma c
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Ranolazine is a moderate to potent inhibitor of P-gp and a mild inhibitor of CYP3A4, and may increase plasma c
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Ranolazine is a moderate to potent inhibitor of P-gp and a mild inhibitor of CYP3A4, and may increase plasma c
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Ranolazine is a substrate for P-gp. Inhibitors of P-gp (e.g. ciclosporin, verapamil) increase plasma levels of
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Ranolazine is a substrate for P-gp. Inhibitors of P-gp (e.g. ciclosporin, verapamil) increase plasma levels of
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Ranolazine is a substrate for P-gp. Inhibitors of P-gp (e.g. ciclosporin, verapamil) increase plasma levels of
Eintrag öffnenRanexa (previously Latixa) · 4.5 · There is a theoretical risk that concomitant treatment of ranolazine with other drugs known to prolong the QTc
Eintrag öffnenRanexa (previously Latixa) · 4.5 · There is a theoretical risk that concomitant treatment of ranolazine with other drugs known to prolong the QTc
Eintrag öffnenRanexa (previously Latixa) · 4.5 · There is a theoretical risk that concomitant treatment of ranolazine with other drugs known to prolong the QTc
Eintrag öffnenRanexa (previously Latixa) · 4.8 · An increased incidence of adverse events was seen among ranolazine treated patients in the RIVER- PCI trial (s
Eintrag öffnenRanexa (previously Latixa) · 4.8 · An increased incidence of adverse events was seen among ranolazine treated patients in the RIVER- PCI trial (s
Eintrag öffnenRanexa (previously Latixa) · 4.8 · An increased incidence of adverse events was seen among ranolazine treated patients in the RIVER- PCI trial (s
Eintrag öffnenRanolazin
Eintrag öffnenranolazine
Eintrag öffnen